

**REFERENCE RELATING TO THE COMPLETED ACQUISITION
BY ALLIANCE MEDICAL GROUP LIMITED OF ASSETS OF IBA
MOLECULAR UK LIMITED USED TO MANUFACTURE
FLUORODEOXYGLUCOSE 18F**

**Notice of provisional findings made under Rule 11.3 of the
Competition and Markets Authority Rules of Procedure for Merger,
Market and Special Reference Groups¹**

1. On 24 March 2014, the Office of Fair Trading (OFT), in exercise of its duty under section 22 of the Enterprise Act 2002 (the Act) referred to the Competition Commission (CC) the completed acquisition by Alliance Medical Group of the manufacturing assets of IBA Molecular UK Limited used for the production of fluorodeoxyglucose 18F (FDG-18) in the UK for investigation and report within a period ending on 7 September 2014.
2. On 1 April 2014 the functions of the CC in relation to the reference were transferred to the Competition and Markets Authority (CMA), under Schedule 5 to the Enterprise and Regulatory Reform Act 2013 and the Schedule to the Enterprise and Regulatory Reform Act 2013 (Commencement No. 6, Transitional Provisions and Savings) Order 2014.

Provisional findings

3. The Inquiry Group appointed to consider this reference has made the following provisional findings on the statutory questions it has to decide pursuant to section 35(1) of the Act:
 - (a) a relevant merger situation has been created; and
 - (b) the creation of that situation has not resulted, or may not be expected to result, in a substantial lessening of competition within the market or markets in the UK for goods or services.
4. The Inquiry Group's reasons are set out in full in the provisional findings report, which is attached to this notice, and are summarised in the summary of the provisional findings report (see note below).

¹ CMA17.

The next steps

5. Anyone wishing to comment on the provisional findings is now invited to provide the Inquiry Group with their reasons in writing as to why these provisional findings should not become final (or, as the case may be, should be varied).
6. These reasons should be received by the Inquiry Manager on behalf of the Inquiry Group by no later than 5pm on 1 August 2014.
7. The Inquiry Group will have regard to any such reasons in making its final decisions on the statutory questions and actions.

(signed) JOHN WOTTON
Group Chair
10 July 2014

Note: A copy of this notice and the summary of the provisional findings report will be placed on the CMA webpages on 10 July 2014. The CMA also proposes to publish the provisional findings report on its [webpages](#) by 10 July 2014. The published version of the provisional findings report will not contain any information which the Inquiry Group considers should be excluded from the report, having regard to the three considerations set out in section 244 of the Act. These omissions are indicated by [✂].

Comments should be made by email to david.fowlis@cma.gsi.gov.uk or in writing to:

David Fowlis
Inquiry Manager
Alliance/IBA merger
Victoria House
Southampton Row
LONDON
WC1B 4AD